Halo naevi with associated vitiligo-like depigmentations: Pathogenetic hypothesis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 6, 2012, Pages 755-761

  Van Geel, N ^a   Speeckaert, R ^a   Lambert, J ^a   Mollet, I ^a   De Keyser, S ^a   De Schepper, S ^a   Brochez, L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE COURSE; FAMILY HISTORY; FEMALE; FOLLOW UP; HALO NEVUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKODERMA; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SKIN BIOPSY; VITILIGO;

ADULT; FEMALE; HUMANS; MALE; NEVUS, HALO; SKIN PIGMENTATION; VITILIGO;

EID: 84861575068     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04160.x     Document Type: Article

References (30)

1. Bystryn JC, Xie Z, Neoplastic hypomelanosis. In:, Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP, eds. The Pigmentary System. Physiology and Pathophysiology. Oxford University Press, New York, 1998: 647-662.
2. Rhodes AR,. Neoplasms. Benign neoplasias, hyperplasias, and dysplasias of melanocytes. In:, Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in General Medicine, 4th edn. McGraw-Hill Co., New York, 1993: 1037.
3. Sotiriadis D, Lazaridou E, Patsatsi A, et al. Does halo nevus without halo exist? J Eur Acad Dermatol Venereol 2006; 20: 1394-1396.
4. Speeckaert R, van Geel N, Vermaelen K, et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011; 24: 334-344.
5. van Geel N, Vandenhaute S, Speeckaert R, et al. Prognostic value and clinical significance of halo nevi regarding vitiligo. Br J Dermatol 2011; 164: 743-749.
6. Ortonne JP, Mosher DB, Fitzpatrick TB,. Topics in Dermatology: Vitiligo and Other Hypomelanoses of Hair and Skin. Plenum Press, New York, 1983: 567-611.
7. Kim HS, Goh BK,. Vitiligo after halo formation around congenital melanocytic nevi. Pediatr Dermatol 2009; 26: 755-756.
8. Itin PH, Lautenschlager S,. Acquired leukoderma in congenital pigmented nevus associated with vitiligo depigmentation. Pediatr Dermatol 2002; 19: 73-75.
9. Stierman SC, Tierney E, Shwayder TA,. Halo congenital nevocellular nevi associated with extralesional vitiligo: case series with review of the literature. Pediatr Dermatol 2009; 26: 414-424.
10. De Vijlder HC, Westerhof W, Schreuder GM, et al. Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA study. Pigment Cell Res 2004; 17: 270-274.
11. Zeff RA, Freitag A, Grin CM, et al. The immune response in halo nevi. J Am Acad Dermatol 1997; 37: 320-324.
12. Schallreuter KU, Kothari S, Elwary S, et al. Molecular evidence that halo in Sutton's naevus is not vitiligo. Arch Dermatol Res 2003; 295: 223-228.
13. Ongenae K, van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
14. Baranda L, Torres-Alvarez B, Moncada B, et al. Presence of activated lymphocytes in the peripheral blood of patients with halo nevi. J Am Acad Dermatol 1999; 41: 567-572.
15. Mandelcorn-Monson RL, Shear NH, Yau E, et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121: 550-556.
16. van Geel NA, Mollet IG, De Schepper S, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigm Cell Mel Res 2010; 23: 375-384.
17. Le Poole IC, Luiten RM,. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 2008; 10: 227-243.
18. Hofmann UB, Bröcker EB, Hamm H,. Simultaneous onset of segmental vitiligo and a halo surrounding a congenital melanocytic naevus. Acta Derm Venereol 2009; 89: 402-406.
19. Westerhof W, d'Ischia M,. Vitiligo puzzle: the pieces fall into place. Pigment Cell Res 2007; 20: 345-359.
20. Musette P, Bachelez H, Flageul B, et al. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol 1999; 162: 1789-1794.
21. Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6: 1053-1059.
22. Rosenberg SA, White DE,. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-84.
23. Tsao H, Millman P, Linette GP, et al. Hyopopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138: 799-802.
24. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
25. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21: 409-414.
26. Becker JC, Guldberg P, Zeuthen J, et al. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999; 113: 1033-1038.
27. Jacobs FM, Aarntzen EHJG, Sibelt LAG, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009; 58: 145-151.
28. Kawakami Y, Robbins PF, Wang RF, et al. The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998; 21: 237-246.
29. Cui Z, Willingham MC,. Halo naevus: a visible case of immunosurveillance in humans? Lancet Oncol 2004; 5: 397-398.
30. Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.